Pipeline

March 6, 2020

Company	Drug/Device	Medical Condition	Status
MiNa Therapeutics	MTL-CEBPA in combination with Keytruda (pembrolizumab)	advanced solid tumors	initiation and first patient treated in phase 1/1b trial
TargoVax SA	ONCOS-102 in combination with Keytruda (pembrolizumab)	advanced anti-PD1 checkpoint inhibitor (CPI) refractory melanoma	patient enrollment completed in phase 1 trial
HUYA Bioscience International	HBI-3000	cardioversion of atrial fibrillation	completion of phase 1 trial
Dynacure	DYN101	myotubular and centronuclear myopathies	first patient dosed in phase 1/2 trial
Allergan plc Editas Medicine	AGN-151587 (EDIT-101)	Leber congenital amaurosis 10 (LCA10)	first patient dosed in phase 1/2 trial
Arrowhead Pharma	ARO-HSD	patients with NASH or suspected NASH	first patients dosed in phase 1/2 trial
DiscGenics	IDCT, allogeneic, injectable discogenic cell therapy	degenerative disc disease	completed enrollment in phase 1/2 trial
Novus Therapeutics	OP0201	pediatrics with acute otitis media	completed enrollment in phase 2a trial
VBI Vaccines	VBI-1901 in combination with either GM-CSF or AS01B, (GlaxoSmithKline)	recurrent GBM	first patient dosed in the second study arm of phase 2a trial
Innovent Biologics	IBI375 (pemigatinib)	advanced cholangiocarcinoma with FGFR2 fusions or rearrangements	first patients dosed in phase 2 trial
Neuraly	NLY01	Parkinson’s disease	first patient dosed in phase 2 trial
Moderna	mRNA-1647	cytomegalovirus	completed enrollment in phase 2 trial
American BriVision	ABV-1505	adult attention-deficit hyperactivity disorder	initiation of phase 2 trial
EpicentRx	AIM-001	tumors	IND approved by FDA
Prevail Therapeutics	PR006	frontotemporal dementia patients with GRN mutation	IND approved by FDA
Ayala Pharmaceuticals	AL101	recurrent or metastatic adenoid cystic carcinoma	Fast Track designation granted by FDA
Genentech	Esbriet (pirfenidone)	adults with unclassifiable interstitial lung disease	Breakthrough Therapy Designation granted by FDA
Sanofi	Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex)	adults with multiple myeloma who have had two previous therapies including lenalidomide and a protease inhibitor	approved by the FDA